The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Renal Osteodystrophy (CKD-Mineral Bone Disorder)

Skeletal manifestation of chronic kidney disease characterized by abnormal bone turnover, mineralization, and volume

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Endokrinoloji department. Book Appointment →

What is Renal Osteodystrophy (CKD-Mineral Bone Disorder)?

Renal osteodystrophy is part of CKD-MBD, including biochemical abnormalities, bone disease, and vascular calcification.

Histologic classification (TMV system): turnover (T), mineralization (M), volume (V) - definitive diagnosis by tetracycline double-labeled bone biopsy.

Pathophysiology involves disrupted vitamin D metabolism (decreased 1α-hydroxylation), phosphate retention, hypocalcemia, and secondary hyperparathyroidism.

FGF23 elevation is an early marker of CKD-MBD, contributing to phosphaturia and reduced calcitriol.

Major forms: osteitis fibrosa (high turnover from PTH excess), adynamic bone disease (low turnover, often iatrogenic), osteomalacia (defective mineralization), mixed disease.

Major contributor to fracture risk and cardiovascular calcification in CKD.

Symptoms

Bone pain (especially weight-bearing areas - hips, knees, lower back).
Proximal muscle weakness, waddling gait.
Pathologic fractures (vertebrae, hip, ribs) with minimal trauma.
Skeletal deformities (rugger jersey spine, brown tumors, slipped epiphyses in children).
Pruritus from elevated calcium-phosphate product.
Vascular calcification, calciphylaxis (calcific uremic arteriolopathy).

Risk Factors

Chronic kidney disease stages 3-5, especially dialysis-dependent ESRD.
Long duration of CKD, poor adherence to phosphate binders.
Diabetes mellitus, advanced age (adynamic bone disease).
Aluminum-containing antacids/binders (aluminum bone disease, less common now).
Excessive calcium-based phosphate binders (vascular calcification).
Vitamin D deficiency, low dietary calcium, immobility.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Bone pain, weakness, or fragility fractures in CKD patients.
  • Persistently elevated PTH (> 9x upper limit), hyperphosphatemia, hypercalcemia.
  • Skin necrosis, painful violaceous plaques (calciphylaxis - emergency).
  • Itching unresponsive to standard antipruritics.
  • Routine CKD-MBD monitoring: calcium, phosphate, PTH, alkaline phosphatase, 25-OH vitamin D.
  • Bone density evaluation, vascular calcification screening (lateral lumbar X-ray, echocardiogram).

Treatment Methods

01
Phosphate control: dietary restriction (800-1000 mg/day), phosphate binders (sevelamer, lanthanum, calcium carbonate/acetate, ferric citrate).
02
Vitamin D analogs: calcitriol or paricalcitol/doxercalciferol (less hypercalcemic) for secondary hyperparathyroidism.
03
Calcimimetics: cinacalcet or etelcalcetide to reduce PTH while controlling calcium and phosphate.
04
Maintain serum PTH in target range (KDIGO: 2-9x upper limit for ESRD; reasonable suppression in pre-dialysis CKD).
05
Avoid aluminum-containing binders; minimize calcium load to reduce vascular calcification.
06
Bisphosphonates only with caution in CKD (eGFR > 30); denosumab use carries hypocalcemia risk.
07
Parathyroidectomy for refractory tertiary hyperparathyroidism (severe symptoms, calciphylaxis).
08
Kidney transplantation often improves CKD-MBD; monitor for tertiary hyperparathyroidism, transplant bone disease.

Which Department to Visit?

You can visit our Endokrinoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Endokrinoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.